The SELECT trial showed that semaglutide reduced major adverse cardiovascular events (heart attack, stroke, cardiovascular death) in adults with obesity and established cardiovascular disease, without requiring a diabetes diagnosis. The FLOW trial showed kidney benefits with semaglutide use in patients with type 2 diabetes and chronic kidney disease. Improvements in hard clinical outcomes like cardiac events, kidney disease, and death are commonly observed with GLP-1 use, and are due to both the direct effects of treating the obesity, and indirect effects of the medications themselves
Discover high-protein, low-carb options that support your weight loss journey with smart meal choices
Austin: Landes Bioscience, 1997: 21531 Murakami K, Sugimoto T, Woo M, et al
Cost or access issues make tirzepatide impractical, as semaglutide has broader insurance coverage and more compounding options
They also have metabolic effects and help decrease insulin resistance
Thats not a prediction
